Discover the Opportunity:
Haptenized Protein
Vaccines

Haptenization is based on proven science, a well-understood mechanism of action, and extensive clinical data, with evidence that it can be used to treat multiple viral infections and any resectable solid tumor.

Learn More

We are proudly sponsoring the World Ovarian Cancer Coalition
Go to website
Learn more
James Passin

James Passin

Founder and Chief
Executive Officer

Kenneth Kovan

Kenneth Kovan

Founder, President and
Chief Operating Officer

David Berd, M.D.

Founder and Chief
Medical Officer

Meet the team

Press Releases

BioVaxys Acquires Clinical Study Management Company and Completes Private Placement
March 16, 2023

VANCOUVER, BC, March 16, 2023 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: [...]

BioVaxys Announces Results from The Ohio State University Pan-Sarbecovirus Animal Study
December 18, 2022

VANCOUVER, BC, December 16th, 2022 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) [...]

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
December 1, 2022

VANCOUVER, BC, December 1st, 2022 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) [...]

BioVaxys Closes First Tranche of Non-Brokered Private Placement
November 28, 2022

Vancouver, British Columbia, November 28, 2022, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) [...]

BioVaxys Announces Completed Private Placement And Debt Settlement
November 9, 2022

Vancouver, British Columbia, November 9, 2022, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) [...]

BioVaxys Announces Debt Settlement
October 27, 2022

Vancouver, British Columbia, October 27, 2022 – BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: [...]

BioVaxys Announces Completed Debt Settlement
October 14, 2022

VANCOUVER, British Columbia, Oct. 14, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) [...]

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
October 6, 2022

Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare VANCOUVER, BC, October [...]

read more news